Skip to main content

Table 1 Univariate analysis of pharmacokinetic parameters and biological or clinical variables

From: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia

   CL(L/day) Kout (day-1) V1(L) V2(L)
n p
Age 44 0.86 0.82 0.90 0.99
Sex male versus female 23 versus 21 0.59 0.53 0.34 0.37
Body surface area (BSA, m2) 44 0.59 0.82 0.76 0.99
Binet stage A or B versus C 27 versus 17 0.89 0.82 0.34 0.99
Treatment RB versus RFC 17 versus 28 0.48 0.82 0.76 0.99
Lymphocytosis 44 0.59 0.30 0.96 0.99
Areas of lymphadenopathy 44 0.59 0.39 0.96 0.51
CD38 positivity (≥30%) versus negativity 21 versus 22 0.88 0.82 0.90 0.99
FCGR F/F versus V/F and V/V 25 versus 19 0.86 0.68 0.90 0.99
IGHV unmutated versus mutated status 10 versus 6 0.37 0.82 0.96 0.99
Cytogenetics
 Isolated del(13q) versus others 8 versus 36 0.37 0.02 0.76 0.23
 Trisomy 12 versus others 10 versus 34 0.59 0.92 0.76 0.37
 Normal caryotype versus others 4 versus 40 0.89 0.39 0.96 0.66
 Del(11q) versus others 10 versus 34 0.37 0.17 0.76 0.17
 Del(17p) versus others 9 versus 35 0.17 0.007 0.17 0.23
 Time to relapse (TTR) 44 0.59 0.82 0.96 0.99
 Time to second treatment (TST) 44 0.37 0.39 0.96 0.99
  1. vs. versus, CL clearance, Kout first-order rate constant of rituximab independent death of latent target antigen, V1 central distribution volume, V2 peripheral distribution volume, RB rituximab bendamustine, RFC rituximab fludarabine cyclophosphamide, FCGR Fc gamma receptor, IGHV immunoglobulin heavy chain variable region. Values were adjusted for multiple testing using the Benjamini–Hochberg method (https://www.sdmproject.com/utilities/?show=FDR), and p < 0.05 considered as significant